Haemonetics (HAE) continues to expand its business, banking on growth drivers like Plasma, Thromboelastography (TEG), Hemostasis Management and the Vascular Closure business. The stock sports a Zacks Rank #1 (Strong Buy). Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. The demand for source plasma has continued to grow due to an expanding end-user market for plasma-derived biopharmaceuticals. The ...